文献速递血栓与止血

纵向D-二聚体分析动态评估癌症患者静脉血栓栓塞风险的前瞻性研究

Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D-Dimer analysis: A prospective study.
PubMed 文献 · J Thromb Haemost · 2020-04-15

该前瞻性研究纳入167例活动性恶性肿瘤患者,基线及每月随访共602次检测D-二聚体,采用联合模型分析纵向轨迹与VTE风险的关系。发生VTE者D-二聚体每月增加34%,未发生者保持稳定;D-二聚体轨迹加倍与VTE风险增加2.8倍独立相关,支持纵向D-二聚体用于个体化动态VTE风险预测。

要点

  • 发生VTE者D-二聚体每月增加34%,未发生者保持稳定。
  • D-二聚体轨迹加倍与VTE风险增加2.8倍独立相关。
  • 纵向D-二聚体轨迹可用于个体化动态VTE风险预测。

核心结论

  • D-二聚体在癌症相关VTE发生前升高,而未发生VTE者保持稳定。
  • 纵向D-二聚体轨迹可推进肿瘤领域个体化VTE风险评估。

研究设计与样本

  • 前瞻性研究纳入167例活动性恶性肿瘤患者,胃肠道59例(35%)、肺56例(34%)、脑50例(30%)、其他2例(1%),转移性疾病74例(44%)。
  • 基线及每月随访共602次检测D-二聚体,中位数0.8 µg/mL(25th-75th百分位:0.4-2.0)。
  • 采用纵向与时间-事件数据联合模型量化D-二聚体轨迹与VTE风险的关联。

主要发现

  • 20例发生VTE,250天VTE风险为12.1%(95%CI 7.8-18.5)。
  • 发生VTE者D-二聚体每月增加34%(0.47 µg/mL/月,95%CI 0.22-0.72,P<.0001)。
  • 未发生VTE者D-二聚体每月变化为-0.06 µg/mL(95%CI -0.15至0.02,P=.121),保持稳定。
  • 联合模型中D-二聚体轨迹加倍与VTE风险增加2.8倍相关(HR=2.78,95%CI 1.69-4.58,P<.0001),独立于既定VTE风险因素。

临床怎么用

  • 可基于个体患者D-二聚体纵向轨迹进行高度个体化的动态VTE风险预测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Venous thromboembolism (VTE) is a frequent complication of cancer. Elevated D-dimer is associated with an increased risk of cancer-associated VTE. Whether changes in D-dimer over time harbor additional prognostic information that may be exploited clinically for dynamic prediction of VTE is unclear. OBJECTIVES: To explore the potential role of longitudinal D-dimer trajectories for personalized prediction of cancer-associated VTE. PATIENTS/METHODS: A total of 167 patients with active malignancy were prospectively enrolled (gastrointestinal: n = 59 [35%], lung: n = 56 [34%], brain: n = 50 [30%], others: n = 2 [1%]; metastatic disease: n = 74 [44%]). D-dimer (median = 0.8 µg/mL [25th-75th percentile: 0.4-2.0]) was measured at baseline and during 602 monthly follow-up visits. Joint models of longitudinal and time-to-event data were implemented to quantify the association between D-dimer trajectories and prospective risk of VTE. RESULTS: VTE occurred in 20 patients (250-day VTE risk = 12.1%, 95% confidence interval [CI], 7.8-18.5). D-dimer increased by 34%/month (0.47 µg/mL/month, 95% CI, 0.22-0.72, P < .0001) in patients who developed VTE, but remained constant in patients who did not develop VTE (change/month = -0.06 µg/mL, 95% CI, -0.15 to 0.02, P = .121). In joint modeling, a doubling of the D-dimer trajectory was associated with a 2.8-fold increase in the risk of VTE (hazard ratio = 2.78, 95% CI, 1.69-4.58, P < .0001). This finding was independent of established VTE risk factors. Highly personalized, dynamic predictions of VTE conditional on individual patients' D-dimer trajectories could be obtained. CONCLUSIONS: D-dimer increases before the onset of cancer-associated VTE, but remains constant over time in patients without VTE. This study represents proof-of-concept that longitudinal trajectories of D-Dimer may advance the personalized assessment of VTE risk in the oncologic setting.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Posch F, Riedl J, Reitter EM, et al. Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D-Dimer analysis: A prospective study. J Thromb Haemost. 2020. PMID: 32073229. doi:10.1111/jth.14774

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。